Scotiabank started coverage on shares of Keros Therapeutics (NASDAQ:KROS – Free Report) in a research report released on Wednesday morning, MarketBeat Ratings reports. The firm issued a sector outperform rating and a $77.00 target price on the stock.
A number of other brokerages also recently issued reports on KROS. HC Wainwright reissued a “buy” rating and set a $100.00 price target on shares of Keros Therapeutics in a report on Tuesday, June 18th. Oppenheimer started coverage on Keros Therapeutics in a research note on Tuesday, June 25th. They issued an “outperform” rating and a $102.00 price target for the company. Truist Financial reiterated a “buy” rating and set a $100.00 price target on shares of Keros Therapeutics in a research report on Tuesday, June 18th. Guggenheim assumed coverage on shares of Keros Therapeutics in a research note on Monday, September 23rd. They issued a “buy” rating and a $96.00 price target on the stock. Finally, Bank of America reduced their price objective on shares of Keros Therapeutics from $81.00 to $76.00 and set a “buy” rating for the company in a research report on Thursday, September 12th. Ten analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock has an average rating of “Buy” and a consensus price target of $89.11.
Read Our Latest Research Report on KROS
Keros Therapeutics Stock Performance
Keros Therapeutics (NASDAQ:KROS – Get Free Report) last issued its earnings results on Wednesday, August 7th. The company reported ($1.25) EPS for the quarter, missing analysts’ consensus estimates of ($1.23) by ($0.02). Keros Therapeutics had a negative return on equity of 44.73% and a negative net margin of 62,012.55%. The company had revenue of $0.04 million during the quarter. During the same quarter last year, the firm earned ($1.27) EPS. Analysts forecast that Keros Therapeutics will post -4.88 EPS for the current year.
Insider Transactions at Keros Therapeutics
In related news, Director Carl L. Gordon sold 250,000 shares of the company’s stock in a transaction dated Tuesday, August 13th. The shares were sold at an average price of $44.01, for a total value of $11,002,500.00. Following the completion of the sale, the director now owns 119,522 shares of the company’s stock, valued at approximately $5,260,163.22. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Insiders own 22.90% of the company’s stock.
Institutional Inflows and Outflows
A number of large investors have recently added to or reduced their stakes in KROS. Point72 Asia Singapore Pte. Ltd. acquired a new position in shares of Keros Therapeutics in the 2nd quarter valued at $128,000. Ameritas Investment Partners Inc. increased its holdings in Keros Therapeutics by 14.5% in the 1st quarter. Ameritas Investment Partners Inc. now owns 2,560 shares of the company’s stock valued at $169,000 after purchasing an additional 324 shares during the last quarter. Quest Partners LLC raised its position in Keros Therapeutics by 23,945.0% in the second quarter. Quest Partners LLC now owns 4,809 shares of the company’s stock valued at $220,000 after purchasing an additional 4,789 shares during the period. XTX Topco Ltd acquired a new position in Keros Therapeutics during the second quarter worth $228,000. Finally, Bayesian Capital Management LP acquired a new position in Keros Therapeutics during the first quarter worth $267,000. 71.56% of the stock is currently owned by institutional investors and hedge funds.
Keros Therapeutics Company Profile
Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.
Recommended Stories
- Five stocks we like better than Keros Therapeutics
- Trading Stocks: RSI and Why it’s Useful
- Taiwan Semiconductor Stock: Buy Now or Wait for Earnings?
- What is Forex and How Does it Work?
- Abbott’s Growth and Dividends Make It a Smart Portfolio Pick
- 3 Monster Growth Stocks to Buy Now
- Citigroup Faces Growing Troubles: Could the Industry Be at Risk?
Receive News & Ratings for Keros Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Keros Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.